Immunic Inc. (NASDAQ:IMUX) saw an upside of 7.26% to $1.92 after adding $0.13 on Tuesday. The 5-day average trading volume is 1,544,947 shares of the company’s common stock. It has gained $1.9150 in the past week and touched a new high 3 times within the past 5 days. An average of 882,022 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 930,351.
IMUX’s 1-month performance is 51.69% or $0.5548 on its low of $1.2511 reached on 12/29/22. The company’s shares have touched a 52-week low of $1.11 and high of $14.50, with the stock’s rally to the 52-week high happening on 01/20/23. YTD, IMUX has achieved 27.86% or $0.4548 and has reached a new high 8 times. However, the current price is down -86.76% from the 52-week high price.
IMUX stock has a beta of 1.65. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.50.
Immunic Inc.’s quick ratio for the period ended September 29 was 7.50, with the current ratio over the same period at 7.50.
For the quarterly period ending September 29 this year, Net income grew 9.1% to -$21.22 million, while revenue of -$21.9 million was -3.2% off the previous quarter. Analysts expected IMUX to announce -$0.66 per share in earnings in its latest quarter, but it posted -$0.69, representing a -4.50% surprise. IMUX stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 12.27 million, with total debt at $1.15 million. Shareholders hold equity totaling $39.26 million.
Let’s look briefly at Immunic Inc. (IMUX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 76.87% to suggest the stock is trending Overbought, with historical volatility in this time period at 93.17%.
The stock’s 5-day moving average is $1.7590, reflecting a +20.44% or $0.3148 change from its current price. IMUX is currently trading +44.91% above its 20-day SMA, -59.68% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +27.92% and SMA200 by-84.67%.
Stochastic %K and %D was 86.98% and 85.88% and the average true range (ATR) pointed at 0.1412. The RSI (14) points at 67.98%, while the 14-day stochastic is at 90.21% with the period’s ATR at 0.1427. The stock’s 9-day MACD Oscillator is pointing at 0.1788 and 0.2746 on the 14-day charts.
In the most recent analyst report for Immunic Inc. (NASDAQ: IMUX), SVB Leerink downgraded it to a Mkt perform rating. They previously had an Outperform rating on the stock.